TABLE 1

FROM:

Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma

M Duvic and C Zhang

Table 1. Prognosis of CTCL patients according to tumour stage at presentation

Stage	Description	Survival
1A	T1, patches and/or plaques involving <10% BSA with no palpable adenopathy	Similar to age-matched controls (Kim et al, 1999; Zackheim et al, 1999)
1B	T2, patches and/or plaque involving at 10% BSA with no palpable adenopathy	67% at 10 years (Kim et al, 1999; Zackheim et al, 1999)
IIA	T1/T2, patches and/or generalised plaque, clinically abnormal lymph nodes
IIB	T3, cutaneous tumours	5 years (Kim and Hoppe, 1999)
III	T4, generalised erythroderma
IVA-B	Pathologically involved lymph nodes or visceral involvement	2.5 years (Kim and Hoppe, 1999)

 BSA=body surface area.